Viracta Therapeutics Inc
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trial… Read more
Viracta Therapeutics Inc (VIRX) - Total Assets
Latest total assets as of September 2024: $21.96 Million USD
Based on the latest financial reports, Viracta Therapeutics Inc (VIRX) holds total assets worth $21.96 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Viracta Therapeutics Inc - Total Assets Trend (2005–2023)
This chart illustrates how Viracta Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Viracta Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Viracta Therapeutics Inc's total assets of $21.96 Million consist of 97.0% current assets and 3.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.7% |
| Accounts Receivable | $281.00K | 0.5% |
| Inventory | $-135.00K | -0.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2023)
This chart illustrates how Viracta Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Viracta Therapeutics Inc's current assets represent 97.0% of total assets in 2023, an increase from 92.1% in 2005.
- Cash Position: Cash and equivalents constituted 21.7% of total assets in 2023, down from 32.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Viracta Therapeutics Inc Competitors by Total Assets
Key competitors of Viracta Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Viracta Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Viracta Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Viracta Therapeutics Inc is currently not profitable relative to its asset base.
Viracta Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.76 | 1.77 | 3.86 |
| Quick Ratio | 0.76 | 1.78 | 3.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.77 Million | $ 28.01 Million | $ 26.91 Million |
Viracta Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Viracta Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.00 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -40.9% |
| Total Assets | $56.69 Million |
| Market Capitalization | $545.23K USD |
Valuation Analysis
Below Book Valuation: The market values Viracta Therapeutics Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Viracta Therapeutics Inc's assets decreased by 40.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Viracta Therapeutics Inc (2005–2023)
The table below shows the annual total assets of Viracta Therapeutics Inc from 2005 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $56.69 Million | -40.94% |
| 2022-12-31 | $95.99 Million | -11.57% |
| 2021-12-31 | $108.55 Million | +124.72% |
| 2020-12-31 | $48.30 Million | +29.71% |
| 2019-12-31 | $37.24 Million | +143.02% |
| 2018-12-31 | $15.32 Million | -55.37% |
| 2017-12-31 | $34.33 Million | -20.59% |
| 2016-12-31 | $43.23 Million | -8.02% |
| 2015-12-31 | $47.00 Million | +6.23% |
| 2014-12-31 | $44.25 Million | +9.18% |
| 2013-12-31 | $40.52 Million | -44.50% |
| 2012-12-31 | $73.02 Million | +59.19% |
| 2011-12-31 | $45.87 Million | -16.39% |
| 2010-12-31 | $54.86 Million | +961.22% |
| 2009-12-31 | $5.17 Million | -59.56% |
| 2008-12-31 | $12.78 Million | -75.99% |
| 2007-12-31 | $53.25 Million | -23.14% |
| 2006-12-31 | $69.28 Million | +26.63% |
| 2005-12-31 | $54.71 Million | -- |